Excel Industries Ltd Q4 FY2026 Concall Summary

Source transcript PDF: https://assets.stockscans.in/docs/ckw7gtbr29z3svhqq50fchr6.pdf

Key Takeaways


Demand Environment & Q4 Recovery


Contract Manufacturing: The Pipeline & Proof Points

Ravi Shroff: "It's typically the inbound that comes in from a customer, you know, seeking a specific query. And I can tell you that, you know, in the few cases that we've had this experience already, the experience has been largely good and successful in being able to carry through some of these opportunities."

Portfolio Mix & Growth Drivers

Ravi Shroff: "Chemistry diversification is a double-edged sword, right? We already have strengths in phosphorus chemistry, for example. So, our current aim or approach is what can we leverage further on areas that we are good at instead of trying to get into areas where we'll be competing other established players."

Capex, Capacity & Capital Allocation

Ravi Shroff: "Your point is noted. We will evaluate this point and discuss it at the Board."

Markets, Trade Policy & Competitive Position


Guidance & Commitments

CommitmentSpecificsTimeline
Contract manufacturing line commissioningDedicated line for November 2025 agreement on streamJuly 2026
New biocide product launchOne more biocide product to be launchedH2 FY27
Anti-dumping findings expectedInvestigation for HCDP and ATMP; findings in normal courseBy September 2026
Capex deploymentINR200-300 crores across Performance Solutions, contract manufacturing, YP derivativesOver next three years
Portfolio mix shiftAgrochemical intermediate proportion to reduce; growth areas are value and margin accretiveGoing forward (undated)
Share buyback evaluationEvaluate and discuss at the BoardNo timeline given

Key Metrics

MetricQ4 FY26
Revenue₹281 cr, +13% YoY
Adjusted EBITDA₹22 cr, +13% YoY
Adjusted EBITDA margin8%
Profit after tax₹13 cr, vs ₹11 cr in Q4 FY25
FY26 revenue₹1,094 cr, +11.8% YoY
FY26 adjusted EBITDA₹112 cr, margin of 10.1%
FY26 profit after tax₹73 cr, margin of 6.7%
Final dividend₹13.75 per share, 275% of face value of ₹5
Net debtZero long-term debt, net cash positive
Capacity utilization65% to 85%, varies by product
Domestic phosphonates market share50% to 55%
Export share of revenue~20%
Planned capex over next 2–3 years₹200 cr to ₹300 cr, with fixed asset turnover of 1–1.5x and expected ROI of 15–20%
Biocides capacity addition2,530 tonnes per annum, operational in H2 FY26
Standalone net cash~₹202 cr